|Articles|July 1, 1999

July 1999
Volume 5
Issue 7

The Food and Drug Administration and Atrial Defibrillation Devices

Author(s)Leway Chen, MD, Anne T. Keane, PA-C, JD, Nathan R. Every, MD, MPH

Download PDF: The Food and Drug Administration and Atrial Defibrillation Devices

Articles in this issue

almost 27 years ago

Article

Hospital Expenditures and Utilization: The Impact of HMOs

almost 27 years ago

Article

The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

almost 27 years ago

Article

Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease

almost 27 years ago

Article

Payor Cost Savings with Endometrial Ablation Therapy

almost 27 years ago

Article

Benign Prostatic Hyperplasia: New Concepts for the Millennium

almost 27 years ago

Article

Breast Cancer Prevention: The Role of Antiestrogens

almost 27 years ago

Article

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

The Food and Drug Administration and Atrial Defibrillation Devices

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Food and Drug Administration and Atrial Defibrillation Devices

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

ATTR-CM Incidence, Prevalence Rose Sharply in the US